Tango Therapeutics, Inc. TNGX

TNGX Company Overview

Tango Therapeutics, Inc. is a biotechnology company focused on developing precision oncology medicines using the concept of synthetic lethality, where the loss of two genes together causes cancer cell death while sparing normal cells. The company operates within the oncology and targeted therapeutics sectors, with a primary emphasis on discovering and developing treatments for genetically defined cancers. Tango’s research platform combines functional genomics, computational biology, and cancer biology to identify novel drug targets associated with tumor suppressor gene loss.

The company’s principal revenue sources have historically included collaboration agreements, research funding, and licensing arrangements, while its long-term strategy centers on commercialization of internally developed oncology therapies. Tango’s pipeline includes small molecule therapies targeting cancers associated with mutations such as MTAP deletion and KRAS pathway alterations. The company was founded in 2017 by scientific founders associated with advances in synthetic lethal drug discovery and has evolved from a discovery-stage biotechnology firm into a clinical-stage oncology company with multiple investigational programs.